CLINICAL_TRIALS
ClinicalTrials.gov record update
An Open-label, Treatment-option Protocol of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma, or CD30-positive Cutaneous T-cell Lymphoma
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT01196208
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:38:01.438922+00:00
- Published At
- 2020-09-21T00:00:00+00:00
- Record Updated At
- 2020-09-21
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Disease, Hodgkin", "Lymphoma, Large-Cell, Anaplastic", "Lymphoma, Non-Hodgkin", "Lymphoma, T-Cell, Cutaneous"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2020-09-21"- protocolSection.identificationModule.nctId
"NCT01196208"- protocolSection.identificationModule.officialTitle
"An Open-label, Treatment-option Protocol of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma, or CD30-positive Cutaneous T-cell Lymphoma"- protocolSection.statusModule.overallStatus
"NO_LONGER_AVAILABLE"- protocolSection.designModule.phases
[]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.